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Abstract 
Background: Reactive hyperemia‑peripheral arterial tonometry (RH‑PAT) is a noninvasive and simple test for evaluat‑
ing the endothelial function. There has been sparse evidence on the usefulness of the RH‑PAT index (RHI) in predicting 
future cardiovascular diseases among diabetic patients.
Methods: Asymptomatic diabetic patients with albuminuria were selected; their medical history and laboratory find‑
ings were evaluated every 3 to 4 months, respectively. The primary outcome was a composite of three‑point major 
adverse cardiovascular events (3‑point MACE): death from cardiovascular causes, acute coronary events, or nonfatal 
stroke. On the contrary, secondary outcomes included a composite of 3‑point MACE, hospitalization for heart failure, 
or chronic kidney disease (CKD) progression. RHI was measured using the Endo‑PAT2000 at the baseline. RHI < 1.67 
was considered to indicate peripheral endothelial dysfunction (PED).
Results: In total, 149 subjects were included (mean age, 61.8 ± 9.2 years; duration of diabetes was 12 years). During 
the follow‑up period (median, 49.7 months), of the 149 subjects, primary outcomes were detected in 12 (1 [2.3%] 
and 11 [10.5%] of those without and with PED, respectively). The presence of PED in baseline measurements signifi‑
cantly increased both primary and secondary outcomes, following adjustment for age, sex, hypertension, glycated 
hemoglobin, low‑density lipoprotein cholesterol, triglyceride, systolic blood pressure, baseline estimated glomerular 
filtration rate, overt proteinuria, duration of diabetes, premedical history of ischemic events, anti‑platelet agents, and 
smoking history (hazard ratio [HR]: 10.95; 95% confidence interval CI 1.00–119.91 for the primary outcome; HR, 4.12; 
95% CI 1.37–12.41 for secondary outcome). In addition, PED could predict secondary outcomes independent of the 
risk score according to the American College of Cardiology/American Heart Association (HR: 3.24; 95% CI 1.14–9.17).
Conclusions: PED can independently predict future cardiovascular events among diabetic patients with albuminuria.
Keywords: Reactive hyperemia, Endothelial function, Type 2 diabetes, Ischemic heart disease, Nonfatal stroke, Heart 
failure, Chronic kidney disease
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Background
The leading cause of death in diabetic patients is athero-
sclerotic cardiovascular disease (ASCVD) [1]. However, 
intensive interventions targeting multifactorial ASCVD 
risk factors in the diabetic population have decreased 
vascular complications and mortality rates, [2] which 
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on traditional ASCVD risk factors [3, 4]. Currently, no 
risk scoring system has been developed based on diabetic 
patients on optimal medical treatment.
Reactive hyperemia-peripheral arterial tonometry 
(RH-PAT) is a simple, noninvasive, automatic test for 
evaluating the endothelial function [5, 6]. RH-PAT index 
(RHI) has been reported to be appropriately correlated 
with flow-mediated dilatation [5] and endothelin-1,[7] 
which are reliable markers of endothelial function. As 
RHI directly reflects endothelial function, it might esti-
mate the residual ASCVD risk in diabetic subjects under 
appropriate medical treatment. Furthermore, endothelial 
dysfunction precedes atherosclerosis, [8] and RHI can 
predict the presence of ASCVD itself [9, 10]. Prospective 
studies confirmed that low levels of RHI could predict 
future cardiovascular events independently in the gen-
eral population [11, 12]. However, there has been sparse 
evidence on the predictability of RHI in addition to con-
ventional risk factors for future ASCVD among diabetic 
patients. Only a small-sized cross-sectional study [13] 
and a prospective study (less than 2 years) [14] reported 
no differences in RHI between the diabetic patients with 
and without coronary artery disease (CAD).
Diabetes itself is an important risk factor for ASCVD 
[14]. As albuminuria is a well-known risk factor for 
endothelial dysfunction [15] and ASCVD, [16] diabetic 
subjects with albuminuria consequently have a high risk 
of ASCVD. In this study, asymptomatic diabetic patients 
with albuminuria had their RHI levels evaluated, and 
future cardiovascular events were prospectively assessed. 
In addition, it was investigated whether RHI can pro-
vide any information alongside established ASCVD risk 
factors including Pooled Cohort Equations (PCE) for 
ASCVD according to the American College of Cardiol-
ogy/American Heart Association [17].
Methods
Study subjects
This was a prospective cohort study of type 2 diabetic 
patients with albuminuria. Eligible patients with type 2 
diabetes were: (i) ≥ 18 years of age, (ii) urinary albumin-
to-creatinine ratio (ACR) ≥ 30  mg of albumin per gram 
of creatinine; and (iii) estimated glomerular filtration 
rate (eGFR) ≥ 30/min/1.73  m2 as recommended by the 
Modification of Diet in Renal Disease (MDRD) criteria 
[18]. Patients were excluded if they had (i) a recent his-
tory of myocardial infarction, cerebral infarction, or 
hospitalization due to heart failure less than 3  months 
before the enrollment, (ii) typical anginal pain aggra-
vated by exercise, (iii) any chest discomfort accompanied 
with dyspnea, or (iv) grade 3 hypertension (systolic blood 
pressure (SBP) ≥ 180  mmHg or diastolic blood pressure 
(DBP) ≥ 110 mmHg) [19].
The cohort subjects were prospectively enrolled, and 
their RHI levels were measured within 3  months of 
enrollment. Their medical history and laboratory find-
ings were followed every 3 or 4  months; cardiovascular 
and renal outcome events and deaths were prospectively 
monitored. The protocol was approved by the Institu-
tional Review Board of the Seoul National University 
Boramae Medical Center, and written informed consent 
was obtained from all participants.
Measurement of reactive hyperemic index
RHI was measured using the Endo-PAT2000 (Itamar 
Medical Ltd., Caesarea, Israel) similar to other previous 
studies [20, 21]. Briefly, after resting for at least 15 min, 
the pressure cuff on the forearm was inflated and main-
tained at 50 mmHg above the SBP to occlude the brachial 
artery. The cuff was deflated 5  min later, and RHI was 
automatically calculated by an internal algorithm based 
on pulse wave amplitude at the baseline and 1 min after 
deflation. RHI < 1.67 was considered to indicate periph-
eral arterial endothelial dysfunction (PED) [20, 21].
Study outcomes
The primary outcome was a composite of three major 
adverse cardiovascular events (3-point MACE) which 
were defined as follows: death from cardiovascular 
causes, acute coronary events, or nonfatal stroke. Sec-
ondary outcomes included a composite of 3-point 
MACE, hospitalization for heart failure, or chronic kid-
ney disease (CKD) progression.
An acute coronary event was defined as hospitalization 
for unstable angina or nonfatal myocardial infarction. 
The onset or worsening of CKD was defined as follows: 
(i) a decrease from baseline in eGFR by 30% or more to 
an eGFR < 60 mL/min per 1.73 m2, (ii) an eGFR < 30 mL/
min per 1.73 m2, (iii) the initiation of renal-replacement 
therapy, or (iv) death from renal disease.
Evaluation for ASCVD risk factors
Plasma glucose and lipid concentrations were meas-
ured enzymatically using a Hitachi Automatic Analyzer 
B2400 (Hitachi, Tokyo, Japan), and glycated hemoglobin 
(HbA1c) levels were measured using a 200FR chemistry 
analyzer (Toshiba, Tokyo, Japan). Serum creatinine levels 
were measured every 3–6  months using an assay based 
on isotope dilution mass spectrometry. The patients’ 
eGFR was calculated using the MDRD Study equation 
[18].
Sex-specific PCE for non-Hispanic whites that esti-
mates the 10-year risk of ASCVD according to the Amer-
ican College of Cardiology/American Heart Association 
[17] was also used to adjust conventional ASCVD risk, as 
no specific equation exists for Koreans.
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Statistical analysis
All data were analyzed using IBM SPSS Statistic 20.0 
for Windows (IBM Inc., Chicago, IL, USA). Demo-
graphic and clinical data between those with and with-
out PED were compared with the Mann–Whitney test, 
an independent t test, and a Chi square test. The Cox 
proportional hazards model was used to investigate the 
predicting factors for primary or secondary outcomes 
with adjustments for sex, age, hypertension, HbA1c, low-
density lipoprotein (LDL) cholesterol, triglyceride, overt 
proteinuria (ACR ≥ 300 mg of albumin per gram of cre-
atinine), baseline e-GFR, premedical history of ischemic 
events, duration of diabetes, anti-platelet agents, and 
smoking history. The independent determining factors 
for PED (RHI < 1.67) were investigated using backward 
multivariable logistic regression. The level of significance 
was set at P < 0.05.
In the previous study, 16% of diabetic subjects with 
albuminuria experienced MACE during 3.1  years of 
follow-up [22]; and previous studies based on general 
population reported approximately 20% difference in 
ASCVD event according to the absence or presence of 
PED [11, 12]. With 0.05, 0.20 and 0.80 of α error, β error, 




In total, 149 subjects were included; the median follow-
up period was 49.7  months (range: 3–69  months). At 
the baseline, mean age was 61.8 ± 9.2 years, and median 
duration of diabetes was 12  years (interquartile range 
[IQR], 7–17 years) (Table 1). Among them, 105 subjects 
(70.5%) had PED. These subjects were significantly older 
than those without PED (62.8 ± 8.7  years vs. 59.4 ± 9.9; 
P = 0.043). Despite no difference in the prevalence of 
hypertension or the proportion of subjects on angioten-
sin receptor blocker (ARB) or angiotensin-converting 
enzyme inhibitor (ACEI) between the two groups, sub-
jects with PED experienced low SBP and DBP compared 
to those without PED (Table 1). The proportion of sub-
jects taking statin at a moderate dose or more [23] was 
67.6% and 75.0% in those with and without PED, respec-
tively (no difference between groups; P = 0.371). Over-
all, only 9 subjects took sodium-glucose cotransporter 2 
(SGLT2) inhibitors, whereas no subject took glucagon-
like peptide 1 receptor analogue (GLP1-RA) at the base-
line (Table 1). No difference was observed in body mass 
index (BMI), HbA1c, lipid profile, eGFR, or ACR. The 
presence or absence of PED was not an indicator of pre-
vious vascular events; however, subjects with PED more 
frequently used anti-platelet agents than subjects with 
RHI ≥ 1.67 (52.4% vs. 31.8%; P = 0.022).
Determinants of the baseline RHI
To investigate the independent determinant of PED at 
the baseline, backward multivariable logistic regression 
was performed incorporating age, sex, BMI, HbA1c, SBP, 
DBP, hypertriglyceridemia, hypertension, smoking his-
tory, anti-platelet agents, and prescriptions of cilostazol 
or statin. In the final model, only age, SBP, hypertriglycer-
idemia, and smoking history showed a correlation (Addi-
tional file  1: Table  S1). Age and current smoking were 
significantly associated with PED (odds ratio [OR], 
1.06; 95% CI 1.02–1.11; P = 0.008; and OR, 2.97; 95% CI 
1.15–7.63; P = 0.024, respectively). On the contrary, SBP 
showed a negative association with the risk of PED (OR 
0.96; 95% CI 0.94–0.99; P = 0.006).
Future cardiorenal events according to RHI
During the follow-up period (median 49.7 months), pri-
mary outcomes were detected in 12 of 149 subjects (1 
[2.3%] and 11 [10.5%] in those without and with PED, 
respectively; P = 0.093; Table  2). No mortality was 
associated with cardiovascular causes. Secondary out-
comes were detected in 37 of 149 subjects (4 [9.1%] vs. 
33 [31.4%] in those without and with PED, respectively; 
P = 0.004).
In unadjusted Cox-regression analysis, the presence of 
PED at the baseline did not increase the risk of the pri-
mary outcomes significantly (hazard ratio [HR], 4.62; 95% 
CI 0.60–35.79; P = 0.143). Subjects with PED experienced 
secondary outcomes more frequently than those without 
PED (HR, 3.45; 95% CI 1.22–9.75; P = 0.019; Table  2). 
After adjusting for age, sex, hypertension, HbA1c, LDL 
cholesterol, triglyceride, proteinuria, duration of diabe-
tes, and premedical history of ischemic events, presence 
of PED increased both primary and secondary outcomes 
(Model 1 in Table 2). This trend persisted following addi-
tional adjustments for SBP, baseline e-GFR, anti-platelet 
agents, and smoking history for both primary (HR, 10.95; 
95% CI 1.00–119.91; P = 0.050; Fig.  1a) and second-
ary outcomes (HR, 4.12; 95% CI 1.37–12.41; P = 0.012; 
Fig. 1b; Model 2 in Table 2).
Subsequent Cox-regression analysis incorporating PCE 
and PED confirmed PED as an independent risk factor 
for secondary outcomes (HR, 3.24; 95% CI 1.14–9.17; 
P = 0.027; Additional file 1: Table S2).
CKD progression was observed in 27 subjects during 
the follow-up period, which was associated with PED at 
the baseline in the fully adjusted model (HR, 3.26; 95% 
CI 1.01–10.50; P = 0.048; Model 2 in Table  2; Fig.  1). 
Among subjects experiencing secondary outcomes, 
those with CKD progression had significantly higher SBP 
(134.9 ± 15.6  mmHg vs. 118.9 ± 12.6  mmHg; P = 0.006) 
and lower eGFR (median eGFR, 61.2 vs. 82.1  mL/
min/1.73  m2; P = 0.023) at the baseline than those 
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Table 1 Baseline clinical characteristics according to peripheral endothelial dysfunction (PED)
PED was defined as RHI < 1.67. All values are expressed in mean ± standard deviation or median (interquartile range) for continuous variables and proportions (%) for 
categorical variables
DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
CRP, c-reactive protein; eGFR, estimated Glomerular filtration rate; ACR, albumin-to-creatinine ratio; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative 
diabetic retinopathy; ARB, angiotensin receptor blocker; ACEI, angiotensin converting enzyme inhibitor; CCB, calcium channel blocker; BB, beta-blocker; SGLT2, 
sodium-glucose cotransporter 2; GLP1-RA, glucagon-like peptide 1 receptor analogue; SU, sulfonylurea; IHD, ischemic heart disease
1 Comparison between those with and without PED using Mann-Whitney test, independent t test and chi-square test
Total (n = 149) No PED (n = 44) PED (n = 105) P1
 Age, year 61.8 ± 9.2 59.4 ± 9.9 62.8 ± 8.7 0.043
 Men, n (%) 79 (53.0) 23 (52.3) 56 (53.3) 0.906
 Duration of DM, years 12.0 (7.0–17.0) 11.0 (7.0–16.0) 13.0 (7.5–18.5) 0.309
 BMI, kg/m2 26.1 (24.1–28.0) 26.9 (24.6–28.4) 26.0 (23.9–27.5) 0.087
 SBP, mmHg 130.4 ± 15.4 134.4 ± 15.2 128.8 ± 15.2 0.042
 DBP, mmHg 77.2 ± 10.6 80.2 ± 12.7 75.9 ± 9.3 0.045
 Hypertension, n (%) 134 (89.9) 39 (88.6) 95 (90.5) 0.733
 HbA1c,  % 7.2 (6.7–7.8) 7.1 (6.8–7.5) 7.2 (6.7–7.9) 0.636
 LDL cholesterol, mg/dL 81.0 (68.5–98.0) 81.0 (69.0–97.8) 80.0 (67.0–94.0) 0.499
 HDL cholesterol, mg/dL 44.0 (37.0–52.0) 43.5 (36.3–55.0) 44.0 (37.0–50.5) 0.528
 Triglyceride, mg/dL 125.0 (88.0–176.5) 108.0 (78.5–156.3) 132.0 (95.5–182.5) 0.057
 hsCRP, mg/L 0.6 (0.3–1.4) 0.7 (0.4–1.3) 0.6 (0.3–1.6) 0.850
 eGFR, mL/min/1.73 m2 79.1 (62.2–92.9) 83.8 (69.1–92.7) 77.8 (61.4–93.0) 0.295
  eGFR ≥ 90, n (%) 46 (30.9) 14 (31.8) 32 (30.5) 0.583
  eGFR 60–89, n (%) 77 (51.7) 24 (54.5) 53 (50.5)
  eGFR 30–59, n (%) 26 (17.4) 6 (13.6) 20 (19.0)
 ACR, mg/g 95.2 (49.9–235.3) 92.4 (50.7–210.5) 97.5 (45.0–251.5) 0.867
 Overt proteinuria, n (%) 32 (21.5) 9 (20.5) 23 (21.9) 0.844
 Diabetic retinopathy
  No 65 (47.4) 21 (51.2) 44 (45.8) 0.645
  NDPR 44 (32.1) 12 (29.3) 32 (33.3)
  PDR 28 (20.4) 8 (19.5) 20 (20.8)
 Current smoker, n (%) 47 (31.5) 10 (22.7) 37 (35.2) 0.134
 ARB or ACEI, n (%) 114 (80.3) 34 (79.1) 80 (80.8) 0.811
 CCB, n (%) 65 (45.8) 22 (51.2) 43 (43.4) 0.396
 BB, n (%) 15 (10.6) 7 (16.3) 8 (8.1) 0.144
 Statin, n (%) 128 (85.9) 37 (81.8) 93 (87.6) 0.545
  No statin 19 (12.8) 7 (15.9) 12 (11.4) 0.746
  Low intensity 26 (17.4) 4 (9.1) 22 (21.0)
  Moderate intensity 102 (68.5) 32 (72.7) 70 (66.7)
  High intensity 2 (1.3) 1 (2.3) 1 (1.0)
 Anti‑platelet, n (%) 69 (46.3) 14 (31.8) 55 (52.4) 0.022
 Anti‑diabetic drugs
  Metformin 140 (94.0) 41 (93.2) 99 (94.3) 0.796
  SGLT2 inhibitors 9 (6.0) 4 (9.1) 5 (4.8) 0.312
  SU or insulin 120 (80.5) 32 (72.7) 88 (83.3) 0.119
 Previous IHD, n (%) 4 (2.7) 0 4 (3.8) 0.189
 Previous stoke, n (%) 4 (2.7) 2 (4.5) 2 (1.9) 0.369
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without CKD progression. Notably, no difference in RHI 
at baseline was observed between them (Table 3).
Discussion
In this study, 149 diabetic patients with albuminuria 
(median duration of diabetes was 12 years) were followed 
for 49.7  months, and the primary outcomes, defined as 
3-point MACE, were detected in 8.1% of study sub-
jects. PED (RHI < 1.67) was an independent risk factor 
for developing primary outcomes following adjustments 
for age, sex, hypertension, HbA1c, LDL cholesterol, tri-
glyceride, SBP, baseline e-GFR, overt proteinuria, dura-
tion of diabetes, premedical history of ischemic events, 
anti-platelet agents, and smoking history. Subjects with 
PED at baseline had 10.95 times higher incidence of pri-
mary outcomes during the follow-up period in the fully 
adjusted model.
Similarly, PED was an independent risk factor for CKD 
progression in this study; subjects with PED showed 3.26 
times higher risk of CKD progression. CKD shares com-
mon risk factors and pathophysiological mechanisms 
with ASCVD [24–26]. The combined risk of ASCVD and 
CKD was increased 4.12 times by PED at the baseline.
Traditionally, diabetes is regarded as a CAD equiva-
lent [14]. However, intensive interventions targeting 
multifactorial ASCVD risk factors in the diabetic popu-
lation have decreased vascular complications and mor-
tality rates [2]. This resulted in a substantial reduction 
in death from cardiovascular causes, [27, 28] and weak-
ened the prediction power of risk prediction based on 
traditional ASCVD risk factors [3, 4]. The estimation of 
the 10-year risk of ASCVD according to the American 
College of Cardiology/American Heart Association by 
PCE [17] was developed based on subjects enrolled in 
the 1970s-1990s; before the 1990s, statin therapy was 
not available. Accordingly, PCE overestimates ASCVD 
risk in modern cohorts [29]. In this study, 69.8% of the 
study subjects took statin with moderate intensity or 
more [23] at the baseline, and their baseline LDL cho-
lesterol was 81.0  mg/dL. Currently, there is no risk 
scoring system developed based on diabetic patients 
under multifactorial treatment.
As the RHI directly reflects endothelial function 
regardless of the presence or absence of traditional 
ASCVD risk factors [11, 12], it could estimate the resid-
ual ASCVD risk independent of well-known ASCVD 
risk factors in diabetic subjects. In this study, PED could 
predict primary outcome only after adjusting ASCVD 
risk factors, which might be a supporting evidence for 
the possible estimation of the residual ASCVD risk by 
RHI. However, Venuraju S et al. recently reported that 
RHI could not predict MACE in diabetic patients [30]. 
Similarly, no difference was reported in coronary artery 
calcification (CAC) according to PED [30]. However, 
only a total of 18 MACE was observed in < 2  years of 
follow-up, and too small number of events for a short 
period might weaken the statistical significance. In 
addition, a wide distribution of baseline CAC observed 
in the study subjects reflects heterogeneity in ASCVD 
risk at the baseline among subjects. This might result 
not only in no association between CAC and RHI but 
also in no difference in MACE rate during the study 
period according to the PED status. However, consider-
ing that CAC reflects subclinical atherosclerosis and is 
useful for predicting ASCVD in asymptomatic diabetic 
patients along with the established cardiovascular risk 
Table 2 Cox Proportional Hazards Analysis for  Cardiovascular Events according to  Peripheral Endothelial Dysfunction 
(PED)
PED was defined as RHI < 1.67. Primary outcome was composed of 3-point major adverse cardiovascular events (MACE); secondary outcome was a composite of 
3-point MACE, hospitalization for heart failure, or chronic kidney disease (CKD)
Model 1: adjusted for age, sex, hypertension, HbA1c, LDL cholesterol, triglyceride, proteinuria, duration of diabetes, and premedical history of ischemic events
Model 2: adjusted for systolic blood pressure, baseline e-GFR, anti-platelet agents, and smoking history in addition to Model 1
1 CKD progression defined as decrease from baseline in eGFR by 30% or more to an eGFR of less than 60 mL/min per 1.73 m2, or an eGFR of less than 30 mL/min per 
1.73 m2 during the follow-up period
* Comparison the number of events between those with and without PED
Events, n (%) Unadjusted Model 1 Model 2
No PED (n = 44) PED (n = 105) P* HR (95% CI) P HR (95% CI) P HR (95% CI) P
Primary outcome 1 (2.3) 11 (10.5) 0.093 4.62 (0.60, 35.79) 0.143 11.49 (1.16, 114.24) 0.037 10.95 (1.00, 119.91) 0.050
Secondary outcome 4 (9.1) 33 (31.4) 0.004 3.45 (1.22, 9.75) 0.019 3.85 (1.31, 11.29) 0.014 4.12 (1.37, 12.41) 0.012
Acute coronary event 1 (2.3) 9 (8.6) 0.161 3.79 (0.48, 29.88) 0.207 9.24 (0.90, 95.36) 0.062 8.05 (0.64, 101.10) 0.106
Stroke 0 2 (1.9) 0.357 – 0.594 – 0.983 – 0.965
Heart failure 0 3 (2.9) 0.257 – 0.498 – 0.953 – 0.858
CKD1 4 (9.1) 23 (21.9) 0.064 2.16 (0.74, 6.26) 0.157 2.17 (0.72, 6.61) 0.171 3.26 (1.01, 10.50) 0.048
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factors, [31, 32], the determination of ASCVD risk by 
PED in addition to CAC should be further investigated 
[33–35].
Low RHI was reported not only in diabetes [13, 36–38] 
but also in metabolic syndrome [39] and nonalcoholic 
fatty liver disease [40]. Diabetic patients demonstrated 
lower RHI levels than the general population [13, 36, 37]. 
In this study, low RHI was detected in approximately 70% 
of the study subjects (105 out of 149 subjects), which was 
relatively higher than previous studies based on the gen-
eral population where this was observed in 23–27% of 
the study subjects [20, 21]. In previous studies including 
Fig. 1 Cumulative probability of primary and secondary outcomes according to peripheral arterial endothelial dysfunction (PED). Cox proportional 
hazards model was used to investigate the effect of PED (RHI < 1.67) on the primary and secondary outcome event rates during the follow‑up 
period with adjustment for sex, age, hypertension, glycated hemoglobin (HbA1c), low density lipoprotein (LDL) cholesterol, triglyceride, overt 
proteinuria, baseline estimated glomerular filtration rate (e‑GFR), premedical history of ischemic events, duration of diabetes, anti‑platelet 
agents, and smoking history. Solid and dashed lines represent cumulative probability of a primary outcome composed of 3‑point major adverse 
cardiovascular events (MACE), b secondary outcome composed of 3‑point MACE, hospitalization for heart failure, or chronic kidney disease (CKD) 
progression, c acute coronary events, and d CKD progression in those with and without PED, respectively. RHI, reactive hyperemia index; MACE, 
major adverse cardiovascular event; CKD, chronic kidney disease; e‑GFR, estimated glomerular filtration rate; CAC, coronary artery calcification; 
ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; MDRD, 
Modification of Diet in Renal Disease; PED, peripheral endothelial dysfunction; PCE, pooled Cohort Equations
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diabetic patients, the mean RHI was 1.69; [13] a find-
ing similar to ours. This study included subjects with 
albuminuria. Albuminuria is a well-known risk factor 
of endothelial dysfunction [15] and ASCVD, [16] which 
might result in a prevalent low RHI in this study.
At the baseline, no difference was observed in 
HbA1c, according to RHI in this study. In diabetic 
subjects, low RHI level was reported to be associated 
with poor glycemic control status [13, 30, 38]; however, 
there has been some controversies regarding this [41]. 
In addition, the median HbA1c in this study was 7.2 
(IQR, 6.7–7.8), a relatively fair level, which might result 
in a negative finding in the association between glyce-
mic level and RHI. On the contrary, lower SBP, age, and 
smoking were independent risk factors for low RHI in 
this study. However, no difference was observed in the 
prevalence of hypertension or the use of antihyperten-
sive medication according to RHI. There is support-
ing information for a positive correlation, [42, 43] and 
a negative correlation [39, 44] between blood pressure 
Table 3 Baseline clinical characteristics according to CKD progression during the follow-up period
All values are expressed in mean ± standard deviation or median (interquartile range) for continuous variables and proportions (%) for categorical variables
CKD progression defined as decrease from baseline in eGFR by 30% or more to an eGFR of less than 60 mL/min per 1.73 m2, or an eGFR of less than 30 mL/min per 
1.73 m2 during the follow-up period
CKD, chronic kidney disease; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; 
HDL, high-density lipoprotein; CRP, c-reactive protein; eGFR, estimated Glomerular filtration rate; ACR, albumin-to-creatinine ratio; NPDR, non-proliferative diabetic 
retinopathy; PDR, proliferative diabetic retinopathy; ARB, angiotensin receptor blocker; CCB, calcium chanel blocker; BB, beta-blocker; IHD, ischemic heart disease
1 Compared between those without and without any events using Mann-Whitney test, independent t test and chi-square test
2 Compared between those with and without CKD progression among subjects with any events using Mann-Whitney test, independent t test and chi-square test
Without any events With any events P1 P2
Entire No CKD progression CKD progression
n = 112 n = 37 n = 10 n = 27
 Age, year 61.0 ± 9.3 64.1 ± 8.5 66.7 ± 8.5 63.6 ± 8.5 0.044 0.323
 Men, n (%) 58 (51.8) 21 (56.8) 7 (70.0) 14 (51.9) 0.599 0.322
 Duration of DM, years 11.0 (7.0–16.8) 14.0 (8.0–17.0) 10.0 (6.0–17.5) 15.0 (11.0–19.0) 0.242 0.319
 BMI, kg/m2 26.4 (24.1–28.0) 25.8 (24.2–27.7) 25.2 (23.9–27.6) 25.8 (24.6–28.7) 0.654 0.468
 SBP, mmHg 130.3 ± 15.0 130.8 ± 16.6 118.9 ± 12.6 134.9 ± 15.6 0.863 0.006
 DBP, mmHg 78.2 ± 10.8 73.8 ± 9.2 72.6 ± 10.7 73.8 ± 8.6 0.017 0.722
 Hypertension, n (%) 100 (89.3) 34 (91.9) 8 (80.0) 26 (96.3) 0.648 0.107
 HbA1c, % 7.2 (6.8–7.8) 7.3 (6.7–8.0) 7.0 (6.6–8.0) 7.3 (6.6–8.0) 0.584 0.625
 LDL cholesterol, mg/dL 81.0 (69.3–94.8) 77.0 (66.0–97.0) 70.5 (64.0–99.3) 78.0 (67.0–99.0) 0.597 0.408
 HDL cholesterol, mg/dL 44.0 (37.0–51.8) 43.0 (38.0–53.0) 49.5 (39.5–55.0) 41.0 (33.0–53.0) 0.661 0.257
 Triglyceride, mg/dL 123.5 (88.0–171.0) 127.0 (91.0–188.0) 111.0 (74.8–180.0) 127.0 (103.0–216.0) 0.333 0.271
 hsCRP, mg/L 0.5 (0.3–1.3) 0.9 (0.4–2.4) 1.9 (0.6–3.3) 0.8 (0.3–1.9) 0.113 0.122
 eGFR, mL/min/1.73 m2 84.7 (70.8–94.3) 61.5 (51.9–72.9) 82.1 (51.0–98.8) 61.0 (49.8–67.0) < 0.001 0.023
 ACR, mg/g 77.5 (44.9–146.4) 265.7 (79.1–636.6) 234.6 (52.7–778.6) 285.0 (174.7–835.4) < 0.001 0.353
 Overt proteinuria, n (%) 13 (11.6) 19 (51.4) 4 (40.0) 15 (55.6) < 0.001 0.401
 RHI 1.50 (1.31–1.85) 1.39 (1.26–1.57) 1.43 (1.23–1.48) 1.37 (1.26–1.59) 0.050 0.625
 Diabetic retinopathy
  No 55 (53.4) 10 (29.4) 2 (22.0) 8 (32.0) 0.038 0.706
  NDPR 29 (28.2) 15 (44.1) 6 (66.7) 9 (36.0)
  PDR 19 (18.4) 9 (26.5) 1 (11.1) 8 (32.0)
 Current smoker, n (%) 36 (32.1) 11 (29.7) 4 (40.0) 7 (25.9) 0.784 0.406
 ARB, n (%) 86 (81.1) 28 (77.8) 6 (66.7) 22 (81.5) 0.662 0.355
 CCB, n (%) 46 (43.4) 19 (52.8) 4 (44.4) 15 (55.6) 0.329 0.563
 BB, n (%) 9 (8.5) 6 (16.7) 0 6 (22.2) 0.168 0.121
 Statin, n (%) 98 (87.5) 30 (81.1) 8 (80.0) 22 (81.5) 0.331 0.919
 Anti‑platelet, n (%) 49 (43.8) 20 (54.1) 6 (60.0) 14 (51.9) 0.276 0.659
 Previous IHD, n (%) 0 4 (10.8) 1 (10.0) 3 (11.1) < 0.001 0.923
 Previous stoke, n (%) 3 (2.7) 1 (2.8) 0 1 (3.7) 0.975 0.558
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and RHI. Heterogeneity in clinical characteristics of 
study subjects among studies might cause a difference 
in the relationship between RHI and blood pressure. 
In addition, inconsistent correlations between RHI and 
well-known ASCVD risk factors have been reported 
not only in blood pressure [30, 39, 42, 44–46] but also 
in age [39, 47, 48]. Age is one of the most important risk 
factors for ASCVD; however, RHI has been reported to 
be positively correlated [39, 47] and negatively corre-
lated [48] with age. The association between RHI and 
blood pressure and/or age should be further investi-
gated in large sized independent studies.
Anti-diabetic medications such as SGLT2 inhibi-
tors or GLP1-RA may influence the endothelial func-
tion, [49] which was not observed in this study. At 
the baseline, only a small number of patients enrolled 
in this study were taking SGLT2 inhibitors (5 of 105 
and 4 of 44 in those with and without PED, respec-
tively), whereas no subject was on GLP1-RA. This study 
enrolled subjects from March 2013 to January 2017; 
in addition, the prescription of SGLT2 inhibitors and 
dulaglutide (the only long-acting GLP1-RA available in 
Korea) commenced in the institution in 2015 and 2016, 
respectively.
Anti-platelet agents are similarly known to improve 
the endothelial function [50]. In this study, subjects in 
the PED group took anti-platelet medications more fre-
quently than those without PED at the baseline. How-
ever, the cross-sectional nature of the comparison of the 
baseline characteristics according to the PED status can-
not show causality, and older age might result in a greater 
rate of prescription in the PED group.
The main limitation of this study was a small sample 
size, which weakened the statistical significance in the 
analysis of each composite secondary endpoint. In addi-
tion, considering that the proportion of CKD progression 
in the secondary outcome was relatively large, the signifi-
cant causal effect of PED on the secondary outcome should 
be interpreted with caution. Despite insufficient statistical 
significance, the trends of each composite secondary end-
point according to the baseline RHI were consistent. Future 
ASCVD risk associated with PED should be validated with 
larger studies. In addition, this result cannot be applied in 
diabetic subjects without albuminuria. Lastly, CAC has 
been recommended for ASCVD risk-stratification [31]. As 
the CAC was not measured, its clinical usefulness alongside 
that of RHI could not be evaluated.
Conclusions
RHI can independently predict future cardiovascular 
events among diabetic patients with albuminuria who 
are under treatment for conventional risk factors. Further 
studies encompassing a larger and diverse population are 
required for confirmation.
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